Cargando…

Validation of absolutely quantitated Ki67 and cyclinD1 protein levels for prognosis of Luminal‐like breast cancer patients

AIMS: To translate a clinical research finding into daily clinical practice requires well‐controlled clinical trials. We have demonstrated the usage of absolute quantitation of Ki67 and cyclinD1 protein levels to improve prognosis of Luminal‐like patients based on overall survival (OS) analysis of a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yu, Guohua, Lyu, Jiahong, Li, Yalun, Zhang, Yunyun, Lyu, Yan, Zhang, Wengfeng, Zhang, Jianbo, Cai, Bocheng, Zhang, Jiandi, Tang, Fangrong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9396173/ https://www.ncbi.nlm.nih.gov/pubmed/35819123 http://dx.doi.org/10.1002/jcla.24601

Ejemplares similares

Combined Use of cyclinD1 and Ki67 for Prognosis of Luminal-Like Breast Cancer Patients
por: Hao, Junmei, et al.
Publicado: (2021)

Improving Prognosis of Surrogate Assay for Breast Cancer Patients by Absolute Quantitation of Ki67 Protein Levels Using Quantitative Dot Blot (QDB) Method
por: Hao, Junmei, et al.
Publicado: (2021)

Developing a routine lab test for absolute quantification of HER2 in FFPE breast cancer tissues using Quantitative Dot Blot (QDB) method
por: Yu, Guohua, et al.
Publicado: (2020)

USP5 Sustains the Proliferation of Glioblastoma Through Stabilization of CyclinD1
por: Li, Gen, et al.
Publicado: (2021)

CyclinD1, a prominent prognostic marker for endometrial diseases
por: Liang, Shuo, et al.
Publicado: (2013)

3D Visualization of the Dynamic Bidirectional Talk Between ER/PR and Her2 Pathways
por: Lyv, Jiahong, et al.
Publicado: (2021)

Ki-67 expression in luminal type breast cancer and its association with the clinicopathology of the cancer
por: YUAN, PENG, et al.
Publicado: (2016)

Intra-tumoral distribution of Ki-67 and Cyclin D1 in ER+ mammary carcinoma: quantitative evaluation
por: Latifa, Mohammedi, et al.
Publicado: (2021)

Immunoexpression of Ki67, p53 and cyclin D1 in osteosarcomas
por: Niculescu, Ştefan Adrian, et al.
Publicado: (2021)

Ki-67 (30-9) scoring and differentiation of Luminal A- and Luminal B-like breast cancer subtypes
por: Viale, Giuseppe, et al.
Publicado: (2019)

Reduced expression of microRNA-206 regulates cell proliferation via cyclinD2 in gliomas
por: YANG, XUE, et al.
Publicado: (2015)

MCM6 versus Ki-67 in diagnosis of luminal molecular subtypes of breast cancers
por: Sadeghian, Dorsay, et al.
Publicado: (2022)

Cyclin D1 and Ki-67 expression in normal, hyperplastic and neoplastic endometrium
por: Shevra, CR, et al.
Publicado: (2015)

The role of cyclin D1 and Ki‐67 in the development and prognostication of thin melanoma
por: Kaufmann, Corina, et al.
Publicado: (2020)

Gene-repressing epigenetic reader EED unexpectedly enhances cyclinD1 gene activation
por: Zhang, Mengxue, et al.
Publicado: (2023)

Inhibition of the CyclinD1 promoter in response to sonic hedgehog signaling pathway transduction is mediated by Gli1
por: Lin, Zhongxiao, et al.
Publicado: (2017)

CyclinD1 protein expressed in pterygia is associated with β-catenin protein localization
por: Tung, Jai-Nien, et al.
Publicado: (2010)

Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer
por: Cheang, Maggie C. U., et al.
Publicado: (2009)

High Throughput, Absolute Determination of the Content of a Selected Protein at Tissue Levels Using Quantitative Dot Blot Analysis (QDB)
por: Qi, Xiaoying, et al.
Publicado: (2018)

CyclinD1 and p57(kip2) as biomarkers in differentiation, metastasis and prognosis of gastric cardia adenocarcinoma
por: Ru, Yi, et al.
Publicado: (2017)

ELISA-like QDB method to meet the emerging need of Her2 assessment for breast cancer patients
por: Yu, Guohua, et al.
Publicado: (2023)

PKC promotes proliferation of airway smooth muscle cells by regulating cyclinD1 expression in asthmatic rats
por: Qiao, Li-fen, et al.
Publicado: (2008)

Quantum Dots-Based Quantitative and In Situ Multiple Imaging on Ki67 and Cytokeratin to Improve Ki67 Assessment in Breast Cancer
por: Yuan, Jing Ping, et al.
Publicado: (2015)

Getting deep in the luminal B breast cancer subtype and its ki67 cut-off value
por: Ciruelos, E, et al.
Publicado: (2011)

Ki67 expression and the effect of neo-adjuvant chemotherapy on luminal HER2-negative breast cancer
por: Horimoto, Yoshiya, et al.
Publicado: (2014)

Can Histological Grade and Mitotic Index Replace Ki67 to Determine Luminal Breast Cancer Subtypes?
por: Oddó, David, et al.
Publicado: (2018)

Risk stratification in luminal-type breast cancer: Comparison of Ki-67 with EndoPredict test results
por: Noske, Aurelia, et al.
Publicado: (2019)

Conventional and digital Ki67 evaluation and their correlation with molecular prognosis and morphological parameters in luminal breast cancer
por: Pons, Laura, et al.
Publicado: (2022)

Quantification of Ki67 Change as a Valid Prognostic Indicator of Luminal B Type Breast Cancer After Neoadjuvant Therapy
por: Tan, Shirong, et al.
Publicado: (2021)

Difference between Luminal A and Luminal B Subtypes According to Ki-67, Tumor Size, and Progesterone Receptor Negativity Providing Prognostic Information
por: Inic, Zorka, et al.
Publicado: (2014)

Ki67 Quantitative Interpretation: Insights using Image Analysis
por: Volynskaya, Zoya, et al.
Publicado: (2019)

BHLHE41 promotes U87 and U251 cell proliferation via ERK/cyclinD1 signaling pathway
por: Wang, Chen, et al.
Publicado: (2019)

Low temperature plasma promoting fibroblast proliferation by activating the NF-κB pathway and increasing cyclinD1 expression
por: Liu, Jin-Ren, et al.
Publicado: (2017)

Ki67 assessment in invasive luminal breast cancer: a comparative study between different scoring methods
por: Lashen, Ayat, et al.
Publicado: (2022)

Objective Quantitation of EGFR Protein Levels using Quantitative Dot Blot Method for the Prognosis of Gastric Cancer Patients
por: Xin, Lei, et al.
Publicado: (2021)

Effects of Cyclooxygenase Inhibitors in Combination with Taxol on Expression of Cyclin D1 and Ki-67 in a Xenograft Model of Ovarian Carcinoma
por: Li, Wei, et al.
Publicado: (2012)

Influence of cyclin D1 splicing variants expression on breast cancer chemoresistance via CDK4/CyclinD1‐pRB‐E2F1 pathway
por: Wang, Jing, et al.
Publicado: (2023)

Combined quantitative measures of ER, PR, HER2, and KI67 provide more prognostic information than categorical combinations in luminal breast cancer
por: Abubakar, Mustapha, et al.
Publicado: (2019)

Cyclin D1 and Ki-67 expression correlates to tumor staging in tongue squamous cell carcinoma
por: Guimarães, Eduardo-Pereira, et al.
Publicado: (2015)

Immunohistochemical Expression of Cyclin D1 and Ki-67 in Primary and Metastatic Oral Squamous Cell Carcinoma
por: Nazar, Maryam, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_lqnsjqlujde672kpr5vhnti6g5